Single digit parts per million detection of molecular residual disease through integrated tumor-informed whole-genome sequencing analysis

In this poster presented at AMP in 2025 Labcorp authors detail how the test named LPDv2 on the UG 100 delivers log-scale performance improvements at reduced cost, positioning it as a highly sensitive, cost-effective platform for ctDNA assessment across multiple solid tumor malignancies.